Gingerly, startups take a virtual approach

The Wall Street Journal has found that the new generation of biotech startups are wrapping their business models around virtual space to scale back on costs but still keep research goals high. For the startup, the model's quite simple: Focus on one asset and pad the cost of failure. For investors, it's just as simple: Invest no more than $2 million or $3 million in the startup's first year, and expect either a lofty return or no harm done. Of course, the obvious pitfall is that contractors may not see eye-to-eye with their clients on a project. Story (sub. req.) | More

Suggested Articles

The Rady Children’s Institute for Genomic Medicine tapped Deloitte to help develop a network of flying drones to deliver genetic testing specimens.

The FDA approved a new, tiny pacemaker from Medtronic that does not require the wiring of separate electrodes between the implant and the heart.

The respiratory care company Vyaire Medical has brought on a new CEO, Gaurav Agarwal, following a year of new product launches.